Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on NxStage Medical

Related NXTM
Benzinga's Top Upgrades, Downgrades For August 22, 2017
The Market In 5 Minutes

In a report published Friday, Jefferies & Company reiterated its Buy rating on NxStage Medical (NASDAQ: NXTM), but lowered its price target from $21.00 to $16.00.

Jefferies noted, “NXTM posted a decent 3Q. Overall HHD grew 17% but US HHD growth again decelerated (+12%) and will remain in check under the current reimbursement environment. The company outlined an increasing number of pipeline opportunities and while achieving increased reimbursement will take time, the substantial long-term HHD opportunity supports our Buy rating.”

NxStage Medical closed on Thursday at $10.61.

Latest Ratings for NXTM

Aug 2017Leerink SwannDowngradesOutperformMarket Perform
Aug 2017BTIG ResearchDowngradesBuyNeutral
Aug 2017JefferiesDowngradesBuyHold

View More Analyst Ratings for NXTM
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings


Related Articles (NXTM)

View Comments and Join the Discussion!